Elizabeth Rees1, Janet Hardy. 1. Department of Palliative Medicine, Royal Marsden Hospital, Sutton, Surrey SM2 5PT.
Abstract
OBJECTIVES: To develop a process of advance consent to enable research to be undertaken in patients in the terminal phase. DESIGN: Feasibility study of an advance consent process to support a randomised controlled trial of two antimuscarinic drugs (hyoscine hydrobromide and glycopyrronium bromide) in the management of noisy respirations associated with retained secretions ("death rattle"). SETTING:Palliative care wards in a major cancer centre. PARTICIPANTS: Patients admitted to a palliative care ward who may develop "death rattle" and thus be eligible for randomisation. MAIN OUTCOME MEASURES: Patient accrual; acceptability of the consent process. RESULTS: Of the 107 patients approached, 58 patients gave advance consent to participate in the study. Of these, 15 patients developed death rattle and were randomised to receive either hyoscine or glycopyrronium; 16 patients died elsewhere; 15 patients died on the palliative care wards but were not randomised; 12 patients are still alive. CONCLUSIONS: Initial assessment suggests that this is a workable consent process allowing research to be undertaken in patients who are unable to give consent at the time of randomisation. Patient accrual rates to date are lower than needed to recruit adequate numbers in the time allotted to answer the research question.
RCT Entities:
OBJECTIVES: To develop a process of advance consent to enable research to be undertaken in patients in the terminal phase. DESIGN: Feasibility study of an advance consent process to support a randomised controlled trial of two antimuscarinic drugs (hyoscine hydrobromide and glycopyrronium bromide) in the management of noisy respirations associated with retained secretions ("death rattle"). SETTING: Palliative care wards in a major cancer centre. PARTICIPANTS: Patients admitted to a palliative care ward who may develop "death rattle" and thus be eligible for randomisation. MAIN OUTCOME MEASURES: Patient accrual; acceptability of the consent process. RESULTS: Of the 107 patients approached, 58 patients gave advance consent to participate in the study. Of these, 15 patients developed death rattle and were randomised to receive either hyoscine or glycopyrronium; 16 patients died elsewhere; 15 patients died on the palliative care wards but were not randomised; 12 patients are still alive. CONCLUSIONS: Initial assessment suggests that this is a workable consent process allowing research to be undertaken in patients who are unable to give consent at the time of randomisation. Patient accrual rates to date are lower than needed to recruit adequate numbers in the time allotted to answer the research question.
Entities:
Keywords:
Biomedical and Behavioral Research; Death and Euthanasia; Empirical Approach
Authors: Lisa Sweet; Dimitrios Adamis; David J Meagher; Daniel Davis; David C Currow; Shirley H Bush; Christopher Barnes; Michael Hartwick; Meera Agar; Jessica Simon; William Breitbart; Neil MacDonald; Peter G Lawlor Journal: J Pain Symptom Manage Date: 2013-12-31 Impact factor: 3.612
Authors: C J Evans; E Yorganci; P Lewis; J Koffman; K Stone; I Tunnard; B Wee; W Bernal; M Hotopf; I J Higginson Journal: BMC Med Date: 2020-07-22 Impact factor: 8.775
Authors: Sophie J Miller; Nishita Desai; Natalie Pattison; Joanne M Droney; Angela King; Paul Farquhar-Smith; Pascale C Gruber Journal: Ann Intensive Care Date: 2015-07-25 Impact factor: 6.925
Authors: Harriëtte J van Esch; Lia van Zuylen; Esther Oomen-de Hoop; Agnes van der Heide; Carin C D van der Rijt Journal: BMC Palliat Care Date: 2018-09-07 Impact factor: 3.234
Authors: Séamus Coyle; Aileen Scott; Amara Callistus Nwosu; Richard Latten; James Wilson; Catriona R Mayland; Stephen Mason; Chris Probert; John Ellershaw Journal: BMJ Open Date: 2016-11-10 Impact factor: 2.692